Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow

References

• Buxbaum J. The amyloidoses. Rheumatology2nd ed., J H Klippel, P A Dieppe. Mosby, London 1998; 8.27.1–10
   Google Scholar
• Kyle R A, Gertz M A. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Jagannath S, Vesole D, Munshi N, Naucke S, Tricot G, Barlogie B. Treatment of AL‐amyloi‐dosis with dexamethazone plus alpha interferon. Leuk Lymphoma 1997; 27: 351–356
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Lust J A, Greipp P R, Witzig T E, Kyle R A. Phase II trial of high‐dose dexamethazone for previously treated immunoglobulin light‐chain amyloidosis. Am J Hematol 1999; 61: 115–119
   PubMedGoogle Scholar
• Wardley A M, Jayson G C, Goldsmith D J A, Venning M C, Ackrill P, Scarffe J H. The treatment of nephritic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethazone. Br J Cancer 1998; 78: 774–776
   PubMed Web of Science ®Google Scholar
• Schwartz R S, Cohen J R, Shrier S L. Therapy of primary amyloidosis with melphalan and prednisone. Arch Intern Med 1979; 139: 1144–1147
   PubMedGoogle Scholar
• Skinner M, Anderson S, Simms R, Falk R, Wang M, Libbey C, Jones L A, Cohen A S. Treatment of 100 patients with primary amyloidosis. A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–298
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Vosburgh E, Falk R H, Sanchorawala V, Reisinger J, Dubrey S, Dember L M, Berk J L, Akpek G, LaValley M, Ohara C, Arkin C F, Wright D G, Skinner M. Dose‐intensive melphalan with blood stem‐cell support for the treatment of AL (amyloid light‐chain) amyloidosis. Survival and responses in 25 patients. Blood 1998; 91: 3662–3670
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282
   PubMed Web of Science ®Google Scholar
• Matsuda M, Gono T, Shimojima Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J Protein Folding Disord 2003; 10: 110–116
   PubMed Web of Science ®Google Scholar
• Kyle R A. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 347–358
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, Koike K, Aizawa M, Ikeda S. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high‐dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 2003; 42: 72–77
   PubMed Web of Science ®Google Scholar
• Huang N, Kawano M M, Harada H, Harada Y, Sakai A, Kuramoto A, Niwa O. Heterogeneous expression of a novel MPC‐1 antigen on myeloma cells. Possible involvement of MPC‐1 antigen in the adhesion of mature myeloma cells to bone marrow of human myelomas. Blood 1993; 82: 3721–3729
   PubMed Web of Science ®Google Scholar
• Kawano M M, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–570
   PubMed Web of Science ®Google Scholar
• Mahmoud M S, Ishikawa H, Fuji Rand, Kawano M M. Induction of CD45 expression and proliferation in U‐266 myeloma cell line by interleukin‐6. Blood 1998; 92: 3887–3897
   PubMed Web of Science ®Google Scholar
• Kawano M M, Mahmoud M S, Huang N, Lisukov I A, Mihara K, Tsujimoto T, Kuramoto A. High proportions of VLA‐5– immature myeloma cells correlated well with poor response to treatment in multiple myeloma. Br J Haematol 1995; 91: 860–864
   PubMed Web of Science ®Google Scholar
• Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau J ‐L. Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis. A report on 21 patients. Br J Haernatol 1998; 101: 766–769
   PubMed Web of Science ®Google Scholar
• Comenzo R L. High‐dose therapy for the treatment of primary systemic amyloidosis. Hematology 1999; 347–357
   Google Scholar
• van Gameren I I, Hazenberg B P C, Jager P L, Smit J W, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid; J Protein Folding Disord 2002; 9: 165–174
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Kawano M M. Biological significance of heterogeneity in human myeloma cells. Int J Hematol 1998; 68: 363–370
   PubMed Web of Science ®Google Scholar
• Bradwell A R, Car‐Smith H D, Mead G P, Harvey T C, Drayson M T. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491
   PubMed Web of Science ®Google Scholar
• Abraham R S, Katzmann J A, Clark R J, Bradwell A R, Kyle R A, Gertz M A. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274–278
   PubMed Web of Science ®Google Scholar
• Gillmore J D, Apperley J F, Lachmann H J, Barrett A J, Madhoo S, Pepys M B, Hawkins P N. Combination chemotherapy for systemic AL amyloidosis. Abstracts of 9th International Symposium on Amyloidosis. 2001; 100
   Google Scholar